Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07167329
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial (BELIEVE-VHL)
The BELIEVE-VHL Trial: A Real-world Longitudinal Study on Belzutifan's Effectiveness, Pharmacogenetics, and Pharmacoeconomics in Von Hippel-Lindau (VHL) Syndrome Using the HIF2α Inhibitor Belzutifan
Sponsor: AC Camargo Cancer Center
Conditions
Endolymphatic Sac Tumor Hemangioblastoma (HB) of the Central Nervous System (CNS) PNET Pheochromocytoma/Paraganglioma Retinal Angiomatous Proliferation Von Hippel Lindau Von Hippel Lindau Disease Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
Interventions
Belzutifan
Updated 1 time since 2025 Last updated: Sep 9, 2025 Started: Jan 1, 2024 Primary completion: Feb 1, 2026 Completion: Jan 1, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07167329, this PHASE2 trial focuses on Endolymphatic Sac Tumor and Hemangioblastoma (HB) of the Central Nervous System (CNS) and remains actively recruiting participants. Sponsored by AC Camargo Cancer Center, it has been updated 1 time since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- AC Camargo Cancer Center
- José Claudio Casali da Rocha
Data source: AC Camargo Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .